Patients who have received a coronary stent, and the clinicians who follow them afterward, sometimes hear two terms that can be easy to confuse: stent thrombosis and restenosis. Understanding stent thrombosis vs restenosis matters because, while both involve a problem occurring at the site of a previously placed stent, they are fundamentally different processes with different timelines, different underlying mechanisms, and different implications for how urgently they need attention. This article lays out the distinction at a general, educational level so patients and caregivers can better understand what their care team may be referring to during follow-up visits.
What Is Stent Thrombosis?
Stent thrombosis refers to the sudden formation of a blood clot inside a previously placed stent. It is an acute event, meaning it can develop rapidly, and it can occur at various points after implantation — in the initial days, months, or in rarer cases, years later. Because a clot can abruptly block blood flow through the artery, stent thrombosis is generally considered a medical emergency. Sudden or severe chest pain, particularly in someone with a known coronary stent, should prompt seeking immediate medical care rather than waiting to see if symptoms resolve on their own.
What Is Restenosis, and How Is It Different?
Restenosis is a gradual, progressive re-narrowing of the artery inside or adjacent to a stent, and it develops over a considerably longer timeframe — typically months rather than hours or days. Unlike stent thrombosis, which involves an acute clot, restenosis is generally related to tissue growth within the stented segment, sometimes described as neointimal hyperplasia, rather than a blood clot forming suddenly. Because restenosis develops slowly, symptoms such as recurrent chest discomfort or reduced exercise tolerance, when they occur, tend to build up gradually rather than appear suddenly, though any new or worsening chest symptoms should still be evaluated by a physician.
Why Is Dual Antiplatelet Therapy Commonly Discussed in This Context?
Dual antiplatelet therapy, or DAPT, refers to the combined use of two medications that reduce the tendency of platelets to clump together and form clots. DAPT adherence is commonly discussed by clinicians as an important factor in reducing the risk of stent thrombosis, particularly in the period following stent implantation while the stented segment is still healing. Because stopping these medications prematurely, without physician guidance, has been associated with increased clotting risk in the literature, patients are generally advised not to discontinue DAPT on their own and to discuss any changes in medication with their prescribing physician first. DAPT is not generally discussed as a primary tool for preventing restenosis, since that process is related to tissue growth rather than clot formation.
How Are Both Conditions Monitored Over Time?
Both stent thrombosis and restenosis are addressed through structured follow-up care after stent placement. Because stent thrombosis is an acute, unpredictable event, monitoring largely centers on patient education about red-flag symptoms and consistent medication adherence. Restenosis, given its gradual nature, is more often identified through scheduled follow-up visits, symptom review, and additional testing if a patient reports recurrent symptoms. In both cases, a qualified interventional cardiologist or cardiology team determines the appropriate follow-up schedule and any additional testing based on the individual patient's history and stent type.
Can restenosis become an emergency like stent thrombosis?
Restenosis itself develops gradually and is not typically an acute emergency in the way stent thrombosis is, though significantly reduced blood flow from advanced restenosis can eventually cause symptoms requiring evaluation. Any sudden or severe chest pain, regardless of suspected cause, should prompt seeking immediate medical care.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.